ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $32.03 million. The enterprise value is $47.34 million.
| Market Cap | 32.03M |
| Enterprise Value | 47.34M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 7.81 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Shares Outstanding | 7.81M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 32.23% |
| Owned by Institutions (%) | 13.07% |
| Float | 5.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.50 |
| Forward PS | n/a |
| PB Ratio | 1.30 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.71, with a Debt / Equity ratio of 0.66.
| Current Ratio | 2.71 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.20% and return on invested capital (ROIC) is -9.27%.
| Return on Equity (ROE) | -15.20% |
| Return on Assets (ROA) | -8.90% |
| Return on Capital (ROIC) | -9.27% |
| Revenue Per Employee | $287,604 |
| Profits Per Employee | -$52,668 |
| Employee Count | 74 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 2.29 |
Taxes
In the past 12 months, ImmuCell has paid $4,442 in taxes.
| Income Tax | 4,442 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.54% in the last 52 weeks. The beta is 0.58, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -20.54% |
| 50-Day Moving Average | 4.70 |
| 200-Day Moving Average | 4.96 |
| Relative Strength Index (RSI) | 39.97 |
| Average Volume (20 Days) | 8,064 |
Short Selling Information
The latest short interest is 6,480, so 0.08% of the outstanding shares have been sold short.
| Short Interest | 6,480 |
| Short Previous Month | 5,021 |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 0.42 |
Income Statement
In the last 12 months, ImmuCell had revenue of $21.28 million and -$3.90 million in losses. Loss per share was -$0.51.
| Revenue | 21.28M |
| Gross Profit | 5.86M |
| Operating Income | -3.79M |
| Pretax Income | -3.89M |
| Net Income | -3.90M |
| EBITDA | -1.17M |
| EBIT | -3.89M |
| Loss Per Share | -$0.51 |
Balance Sheet
The company has $960,347 in cash and $16.27 million in debt, giving a net cash position of -$15.31 million or -$1.96 per share.
| Cash & Cash Equivalents | 960,347 |
| Total Debt | 16.27M |
| Net Cash | -15.31M |
| Net Cash Per Share | -$1.96 |
| Equity (Book Value) | 24.64M |
| Book Value Per Share | 3.15 |
| Working Capital | 7.16M |
Cash Flow
In the last 12 months, operating cash flow was -$1.49 million and capital expenditures -$1.28 million, giving a free cash flow of -$2.77 million.
| Operating Cash Flow | -1.49M |
| Capital Expenditures | -1.28M |
| Free Cash Flow | -2.77M |
| FCF Per Share | -$0.36 |
Margins
Gross margin is 27.55%, with operating and profit margins of -17.82% and -18.31%.
| Gross Margin | 27.55% |
| Operating Margin | -17.82% |
| Pretax Margin | -18.29% |
| Profit Margin | -18.31% |
| EBITDA Margin | -5.48% |
| EBIT Margin | -18.29% |
| FCF Margin | -13.02% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | -0.05% |
| Earnings Yield | -12.17% |
| FCF Yield | -8.65% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 25, 1990. It was a reverse split with a ratio of 1:100.
| Last Split Date | Jul 25, 1990 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
ImmuCell has an Altman Z-Score of 1.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.03 |
| Piotroski F-Score | 2 |